Merck fails to block Pfizer’s RSV vaccine trade mark

Intellectual Property 2026-01-19 11:02 pm By Andy Sidler | Melbourne

Merck KGaA has failed to block Pfizer’s ‘Abrysvo’ trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities.